These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 29669262)

  • 1. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
    Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine.
    Yamamoto H; Imai K
    Semin Oncol; 2019 Jun; 46(3):261-270. PubMed ID: 31537299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    Sorscher S
    Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
    Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
    Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
    Nádorvári ML; Lotz G; Kulka J; Kiss A; Tímár J
    Pathol Oncol Res; 2024; 30():1611719. PubMed ID: 38655493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of MSI Cancer: Facts and Hopes.
    Wilbur HC; Le DT; Agarwal P
    Clin Cancer Res; 2024 Apr; 30(8):1438-1447. PubMed ID: 38015720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
    Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing.
    Saeed OAM; Mann SA; Luchini C; Huang K; Zhang S; Sen JD; Piredda ML; Wang M; Baldrige LA; Sperling RM; Curless KL; Cheng L
    Hum Pathol; 2021 Sep; 115():10-18. PubMed ID: 34052294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
    Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
    Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.